Bepridil up-regulates cardiac Na + channels as a long-term effect by blunting proteasome signals through inhibition of calmodulin activity

British Journal of Pharmacology

Volumn 157, Issue 3, 2009, Pages 404-414

  Kang, L ^a   Zheng, M Q ^a   Morishima, M ^a   Wang, Y ^a   Kaku, T ^a   Ono, K ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Anti electrical remodelling; Bepridil; Calmodulin; Na + channel; Post transcriptional; Proteasome

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BEPRIDIL; CALMODULIN; CYCLOHEXIMIDE; MESSENGER RNA; N (6 AMINOHEXYL) 5 CHLORO 1 NAPHTHALENESULFONAMIDE; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; PROTEASOME; UBIQUITIN; VOLTAGE GATED SODIUM CHANNEL; ANTIARRHYTHMIC AGENT; ENZYME ACTIVATOR; MUSCLE PROTEIN; PROTEIN SUBUNIT; SCN5A PROTEIN, HUMAN; SODIUM CHANNEL;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HEART MUSCLE CELL; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS INHIBITION; RAT; SIGNAL TRANSDUCTION; SODIUM CURRENT; TIME; UPREGULATION; ANIMAL; BIOSYNTHESIS; CELL CULTURE; DOSE RESPONSE; DRUG ANTAGONISM; GENETICS; HEART MUSCLE; METABOLISM; NEWBORN; PATCH CLAMP; PHYSIOLOGY; WISTAR RAT;

ANIMALS; ANIMALS, NEWBORN; ANTI-ARRHYTHMIA AGENTS; BEPRIDIL; CALMODULIN; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATORS; HUMANS; MUSCLE PROTEINS; MYOCARDIUM; MYOCYTES, CARDIAC; PATCH-CLAMP TECHNIQUES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN SUBUNITS; RATS; RATS, WISTAR; SODIUM CHANNELS; TIME FACTORS; UP-REGULATION;

EID: 70349897786     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00174.x     Document Type: Article

References (40)

1. + channel (H1) by the ubiquitin-protein ligase Nedd4. FEBS Lett 466: 377-380.
2. Alexander SPH, Mathie A, Peters JA (2008). Guide to receptors and channels (GRAC), 3rd edn. Br J Pharmacol 153 (Suppl. 2): S1-S209.
3. Ashikaga K, Kobayashi T, Kimura M, Owada S, Sasaki S, Iwasa A et al. (2006). Effects of amiodarone on electrical and structural remodeling induced in a canine rapid pacing-induced persistent atrial fibrillation model. Eur J Pharmacol 536: 148-153.
4. v1.5 is regulated by Nedd4-2 mediated ubiquitination. Circ Res 95: 284-291.
5. Benet LZ (1985). Pharmacokinetics and metabolism of bepridil. Am J Cardiol 55: 8C-13C.
6. Berger F, Borchard U, Hafner D (1989). Effects of the calcium entry blocker bepridil on repolarizing and pacemaker currents in sheep cardiac Purkinje fibres. Naunyn Schmiedebergs Arch Pharmacol 339: 638-646. (Pubitemid 19159821)
7. Boutillier AL, Kienlen-Campard P, Loeffler JP (1999). Depolarization regulates cyclin D1 degradation and neuronal apoptosis: a hypothesis about the role of the ubiquitin/proteasome signalling pathway. Eur J Neurosci 11: 441-448.
8. Brembilla-Perrot B, Allot E, Clementy J, Cosnay P, Djiane P, Fauchier JP et al. (1992). Evaluation of bepridil efficacy by electrophysiologic testing in patients with recurrent ventricular tachycardia: comparison of two regimens. Cardiovasc Drugs Ther 6: 187-193.
9. Fahmi AI, Patel M, Stevens EB, Fowden AL, John JE III, Lee K et al. (2001). The sodium channel β-subunit SCN3b modulates the kinetics of SCN5a and is expressed heterogeneously in sheep heart. J Physiol 537: 693-700.
10. Fujiki A, Tsuneda T, Sugao M, Mizumaki K, Inoue H (2003). Usefulness and safety of bepridil in converting persistent atrial fibrillation to sinus rhythm. Am J Cardiol 92: 472-475.
11. Fujiki A, Tsuneda T, Sakabe M, Nakagawa K, Mizumaki K, Hirai T et al. (2004). Maintenance of sinus rhythm and recovery of atrial mechanical function after cardioversion with bepridil or in combination with aprindine in long-lasting persistent atrial fibrillation. Circ J 68: 834-839. (Pubitemid 39243804)
12. Hara Y, Nakaya H (1995). SD-3212, a new class I and IV antiarrhythmic drug: a potent inhibitor of the muscarinic acetylcholinereceptor-operated potassium current in guinea-pig atrial cells. Br J Pharmacol 116: 2750-2756.
13. + channel inactivation gating. Circ Res 75: 114-122.
14. Hollingshead LM, Faulds D, Fitton A (1992). Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris. Drugs 44: 835-857.
15. Itoh H, Ishikawa T, Hidaka H (1984). Effects on calmodulin of bepridil, an antianginal agent. J Pharmacol Exp Ther 230: 737-741. (Pubitemid 14040398)
16. Izumi D, Chinushi M, Watanabe H, Washizuka T, Okamura K, Komura S et al. (2007). Bepridil for drug-refractory ventricular tachyarrhythmias. Intern Med 46: 119-124.
17. Kamiya K, Niwa R, Mitcheson JS, Sanguinetti MC (2006). Molecular determinants of hERG channel block. Mol Pharmacol 69: 1709-1716.
18. Kawahara H, Yokosawa H (1994). Intracellular calcium mobilization regulates the activity of 26 S proteasome during the metaphaseanaphase transition in the ascidian meiotic cell cycle. Dev Biol 166: 623-633.
19. v1.5 channel current: comparison with amiodarone and E-4031. Eur J Pharmacol 430: 149-157.
20. Levy S, Cointe R, Metge M, Faugere G, Valeix B, Gerard R (1984). Bepridil for recurrent sustained ventricular tachycardias: assessment using electrophysiologic testing. Am J Cardiol 54: 579-581. (Pubitemid 14073247)
21. + channels. J Pharmacol Exp Ther 291: 562-568.
22. Miyaji K, Tada H, Fukushima Kusano K, Hashimoto T, Kaseno K, Hiramatsu S et al. (2007). Efficacy and safety of the additional bepridil treatment in patients with atrial fibrillation refractory to class I antiarrhythmic drugs. Circ J 71: 1250-1257. (Pubitemid 47195342)
23. Nagatomo T, Fan Z, Ye B, Tonkovich GS, January CT, Kyle JW et al. (1998). Temperature dependence of early and late currents in human cardiac wild-type and long Q-T AKPQ Na+ channels. Am J Physiol 275: H2016-H2024. (Pubitemid 128731569)
24. Nakazato Y, Yasuda M, Sasaki A, lida Y, Kawano Y, Nakazato K et al. (2005). Conversion and maintenance of sinus rhythm by bepridil in patients with persistent atrial fibrillation. Circ J 69: 44-48.
25. Nawada T, Tanaka Y, Hisatome I, Sasaki N, Ohtahara A, Kotake H et al. (1995). Mechanism of inhibition of the sodium current by bepridil in guinea-pig isolated ventricular cells. Br J Pharmacol 116: 1775-1780.
26. Nishida K, Fujiki A, Sakamoto T, Iwamoto J, Mizumaki K, Hashimoto N et al. (2007). Bepridil reverses atrial electrical remodeling and L-type calcium channel downregulation in a canine model of persistent atrial tachycardia. J Cardiovasc Electrophysiol 18: 765-772. (Pubitemid 46934525)
27. Prystowsky EN (1992). Effects of bepridil on cardiac electrophysiologic properties. Am J Cardiol 69: 63D-67D.
28. + channel expression in Xenopus oocytes by β1 subunits. J Biol Chem 270: 25696-25701.
29. + channel by bepridil in isolated guinea-pig ventricular myocytes. Eur J Pharmacol 314: 373-379.
30. Sato T, Costa AD, Sai to T, Ogura T, lshida H, Garlid KD et al. (2006). Bepridil, an antiarrhythmic drug, opens mitochondrial KATP channels, blocks sarcolemmal KATP channels, and confers cardioprotection. J Pharmacol Exp Ther 316: 182-188.
31. Schaeffer P, Lugnier C, Stoclet JC (1991). Interactions of calmodulin antagonists with calcium antagonists binding sites. Eur J Pharmacol 206: 325-332.
32. Shen C, Ye Y, Robertson SE, Lau AW, Mak DO, Chou MM (2005). Calcium/calmodulin regulates ubiquitination of the ubiquitin-specific protease TRE17/USP6. J Biol Chem 280: 35967-35973. (Pubitemid 41633865)
33. Shinagawa K, Shiroshita-Takeshita A, Schram G, Nattel S (2003). Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: insights into the mechanism of the superior efficacy of amiodarone. Circulation 107: 1440-1446. (Pubitemid 36350745)
34. 2+ channel by bepridil. Pharmacology 74: 174-181.
35. Ks, in guinea-pig ventricular myocytes. Br J Pharmacol 128: 1733-1738.
36. 2+ channels in neonatal rat heart. J Mol Cell Cardiol 42: 1045-1053.
37. 2+ exchange current in guinea pig cardiac ventricular myocytes. Jpn J Pharmacol 85: 370-375.
38. 2+ channel through distinct mechanisms. Mol Pharmacol 69: 1684-1691.
39. Yatani A, Brown AM, Schwartz A (1986). Bepridil block of cardiac calcium and sodium channels. J Pharmacol Exp Ther 237: 9-17. (Pubitemid 16116336)
40. Zimmer M, Hofmann F (1987). Differentiation of the drug-binding sites of calmodulin. Eur J Biochem 164: 411-420.